NASDAQ:ECYT - Endocyte Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $17.26 -0.06 (-0.35 %) (As of 07/15/2018 04:00 PM ET)Previous Close$17.26Today's Range$16.97 - $17.4752-Week Range$1.17 - $17.42Volume534,692 shsAverage Volume1.65 million shsMarket Capitalization$1.20 billionP/E Ratio-17.26Dividend YieldN/ABeta0.56 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana. Receive ECYT News and Ratings via Email Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:ECYT CUSIP29269A10 Webwww.endocyte.com Phone765-463-7175 Debt Debt-to-Equity RatioN/A Current Ratio37.86 Quick Ratio37.86 Price-To-Earnings Trailing P/E Ratio-17.26 Forward P/E Ratio-24.66 P/E GrowthN/A Sales & Book Value Annual Sales$70,000.00 Price / Sales17,136.71 Cash FlowN/A Price / CashN/A Book Value$1.99 per share Price / Book8.67 Profitability EPS (Most Recent Fiscal Year)($1.00) Net Income$-55,060,000.00 Net Margins-70,510.81% Return on Equity-34.20% Return on Assets-32.76% Miscellaneous Employees44 Outstanding Shares69,500,000Market Cap$1,199.60 Endocyte (NASDAQ:ECYT) Frequently Asked Questions What is Endocyte's stock symbol? Endocyte trades on the NASDAQ under the ticker symbol "ECYT." How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) posted its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative net margin of 70,510.81% and a negative return on equity of 34.20%. View Endocyte's Earnings History. What price target have analysts set for ECYT? 4 analysts have issued 1-year price targets for Endocyte's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next year. This suggests that the stock has a possible downside of 59.4%. View Analyst Ratings for Endocyte. What is the consensus analysts' recommendation for Endocyte? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Endocyte? Endocyte saw a increase in short interest in June. As of June 29th, there was short interest totalling 8,046,703 shares, an increase of 125.7% from the June 15th total of 3,565,788 shares. Based on an average daily trading volume, of 2,063,456 shares, the short-interest ratio is presently 3.9 days. Approximately 14.4% of the shares of the stock are short sold. View Endocyte's Current Options Chain. Who are some of Endocyte's key competitors? Some companies that are related to Endocyte include Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Intercept Pharmaceuticals (ICPT) and Horizon Pharma (HZNP). Who are Endocyte's key executives? Endocyte's management team includes the folowing people: Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)Mr. Michael T. Andriole, Chief Financial Officer (Age 45)Ms. Katherine K. Parker, VP of HR (Age 53)Dr. Alison A. Armour, Chief Medical Officer (Age 54)Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52) Has Endocyte been receiving favorable news coverage? Media stories about ECYT stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Endocyte earned a daily sentiment score of 0.19 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. How do I buy shares of Endocyte? Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endocyte's stock price today? One share of ECYT stock can currently be purchased for approximately $17.26. How big of a company is Endocyte? Endocyte has a market capitalization of $1.20 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe. How can I contact Endocyte? Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175. MarketBeat Community Rating for Endocyte (NASDAQ ECYT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 270 (Vote Outperform)Underperform Votes: 202 (Vote Underperform)Total Votes: 472MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?